Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330965 · ClinicalTrials.gov registry record
Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
A clinical trial of Secondary Progressive Multiple Sclerosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 36
- Enrollment target
- 13
- Study locations
NCT02330965 is a study of Secondary Progressive Multiple Sclerosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants, below the 493-participant average among 8 other Secondary Progressive Multiple Sclerosis trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT02330965, a study of Secondary Progressive Multiple Sclerosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
- PROCEDURE CSF collection by lumbar puncture (Optional)
Study Locations (13)
California
- Jordan Research & Education Institute: Sutter Alta Bates Summit - Berkeley
- University of Southern California - Los Angeles
- University of California, Davis - Sacramento
Michigan
- University of Michigan Health System -Multiple Sclerosis Center - Ann Arbor
- Henry Ford Health System - Detroit
Colorado
- University of Colorado - Aurora
Minnesota
- Minneapolis Clinic of Neurology - Golden Valley
New Mexico
- University of New Mexico: Health Sciences Center - Albuquerque
New York
- South Shore Neurologic Associates - Multiple Sclerosis Care Center - Patchogue
North Carolina
- Carolinas Medical Center (CMC) - Charlotte
Ohio
- Cleveland Clinic: Mellen Center for Multiple Sclerosis - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-07-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330965
The ClinicalTrials.gov registry entry for NCT02330965 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 493-participant average among 8 other Secondary Progressive Multiple Sclerosis trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Secondary Progressive Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Blood Draw is the first listed.
NCT02330965 reports 13 study locations spanning 10 distinct geographic areas - top geographies include California, Michigan, Colorado.
Frequently Asked Questions
What is clinical trial NCT02330965 about?
NCT02330965 is a clinical study titled "Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis". The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with S...
What is the current status of trial NCT02330965?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2014-12. Estimated completion is 2017-07-12.
What conditions does trial NCT02330965 study?
This clinical trial studies the following conditions: Secondary Progressive Multiple Sclerosis.
What interventions are being tested in trial NCT02330965?
The interventions under investigation include: Blood Draw (PROCEDURE), CSF collection by lumbar puncture (Optional) (PROCEDURE).
Who is sponsoring clinical trial NCT02330965?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330965 being conducted?
This trial has 13 study locations across California, Colorado, Michigan, Minnesota, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Progressive Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
RECRUITING · Phase 2
-
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.